SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Dyax Corp. and Sigma-Tau Pharmaceuticals Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for Hereditary Angioedema; Dyax to Get $2.5 Million Upfront; Eligible to Receive Over $100 Million